Terbium-161 theranostics

AVAILABLE NOW 


About

Founded in 2021, TerThera strives to meet the growing global demand for radionuclides in cancer healthcare by providing a highly sustainable and uninterrupted supply of Terbium-161 for use in radioligand therapy. 

 

Our product

Terbium-161 HCl produced at the highest radiochemical grade under non-GMP conditions, available in 0.05M HCl Solution. Terbium-161 is exchangable for any radiolanthanide in terms of chelation and radiolabeling.

 

 

Latest news

25-SEP-2024 At TerThera we are looking forward to the 37th Annual Congress of the European Association of Nuclear Medicine (EANM) in Hamburg from 19-23 October. 




Radiation Safety

Using PSMA and SST analogues, Terbium-161 has shown excellent bioequivalence presenting a biodistribution comparable to the currently used radiolanthanides. Additionally, the 16-fold increase in Auger and conversion electrons is expected to improve the cellular absorbed dose

 

Radioligand Therapy

Terbium-161, compared to current standard radiolanthanides, provides for an immediate decrease in dose rate allowing a significant improvement in general radiation safety. This optimization of radiation safety may extend current treatment room capacity for Radioligand Therapy.

 

Imaging

Allowing optimization of the SPECT reconstruction parameters, Terbium-161 may provide for higher spatial resolution SPECT imaging, leading to the detection of smaller lesions that provides input for a further optimized treatment plan.

 



Terbium-161 theranostics

AVAILABLE NOW